The Current and Potential Clinical Relevance of Heart Failure Biomarkers

Current Heart Failure Reports

Volumn 12, Issue 5, 2015, Pages 318-327

  Gandhi, Parul U ^a,b   Testani, Jeffrey M ^b   Ahmad, Tariq ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Heart failure; Natriuretic peptides

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 18; INTERLEUKIN 33; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; PROTEIN; SACUBITRIL PLUS VALSARTAN; ST2 PROTEIN; TROPONIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

CLINICAL TRIAL (TOPIC); EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; REVIEW; BLOOD; DRUG MONITORING; METHODOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

BIOMARKERS; DRUG MONITORING; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PROGNOSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84941994418     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-015-0268-2     Document Type: Review

References (69)

1. Katz AM. The "modern" view of heart failure: how did we get here? Circ Heart Fail. 2008;1:63–71.
2. Mozaffarian D et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322. doi:10.1161/CIR.0000000000000152.
3. Yancy CW et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327. doi:10.1161/CIR.0b013e31829e8776.
4. Ahmad T et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail. 2014;2:477–88. doi:10.1016/j.jchf.2014.02.005. This reference outlines the current state of biomarker research and provides a guide for how to design trials to appropriately study biomarkers going forward.
5. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949–52. doi:10.1161/CIRCULATIONAHA.106.683110.
6. van Kimmenade RR, Januzzi Jr JL. Emerging biomarkers in heart failure. Clin Chem. 2012;58:127–38. doi:10.1373/clinchem.2011.165720. This paper delineates the criteria for a useful biomarker in heart failure and describes some important candidate markers.
7. Munagala VK, Burnett Jr JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29:707–69. doi:10.1016/j.cpcardiol.2004.07.002.
8. Januzzi Jr JL et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–54. doi:10.1016/j.amjcard.2004.12.032.
9. Maisel AS et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7. doi:10.1056/NEJMoa020233.
10. Costello-Boerrigter LC et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–53. doi:10.1016/j.jacc.2005.09.025.
11. Weinberg EO et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721–6.
12. Sanada S et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.
13. Weinberg EO et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–6.
14. Seki K et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684–91.
15. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–40. doi:10.1038/nrd2660.
16. Januzzi Jr JL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607–13.
17. Ky B et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180–7. doi:10.1161/CIRCHEARTFAILURE.110.958223.
18. Gaggin HK et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2:65–72. doi:10.1016/j.jchf.2013.10.005.
19. Jougasaki M, Burnett Jr JC. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000;66:855–72.
20. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823–9. doi:10.1373/clinchem.2005.051110.
21. Peacock WF et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011;18:947–58. doi:10.1111/j.1553-2712.2011.01150.x.
22. von Haehling S et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12:484–91. doi:10.1093/eurjhf/hfq031.
23. Ahmad T, Felker GM. Subcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn? J Am Coll Cardiol. 2012;60:2313–5. doi:10.1016/j.jacc.2012.08.991.
24. McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:10.1056/NEJMoa1409077.
25. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2:663–70. doi:10.1016/j.jchf.2014.09.001.
26. Packer M et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61. doi:10.1161/CIRCULATIONAHA.114.013748.
27. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi Jr JL. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6:1206–13. doi:10.1161/CIRCHEARTFAILURE.113.000457.
28. Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7:418–26. doi:10.1161/CIRCHEARTFAILURE.113.001036.
29. Maisel A et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014;114:737–42. doi:10.1016/j.amjcard.2014.05.062.
30. Peacock WF. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin. Clin Chem Lab Med. 2014;52:1433–5. doi:10.1515/cclm-2014-0222.
31. Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1–20. doi:10.1016/j.jchf.2012.10.002. This paper is an outstanding review of the current state of research and understanding of heart failure.
32. Januzzi Jr JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012;33:2265–71. doi:10.1093/eurheartj/ehs191. This paper explains the use of troponin in heart failure and discusses the various etiologies of troponin release in heart failure.
33. Peacock WFt et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26. doi:10.1056/NEJMoa0706824.
34. Latini R et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116:1242–9. doi:10.1161/CIRCULATIONAHA.106.655076.
35. Motiwala SR et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. J Cardiovasc Transl Res. 2015;8:164–72. doi:10.1007/s12265-015-9618-4.
36. Metra M et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196–206. doi:10.1016/j.jacc.2012.11.005.
37. Anand IS et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–34. doi:10.1161/CIRCULATIONAHA.104.508465.
38. Rauchhaus M et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–7.
39. Chung ES et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–40. doi:10.1161/01.CIR.0000077913.60364.D2.
40. Mann DL et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–602. doi:10.1161/01.CIR.0000124490.27666.B2.
41. Petersen JW, Felker GM. Inflammatory biomarkers in heart failure. Congest Heart Fail. 2006;12:324–8.
42. Kempf T et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054–60.
43. Anand IS et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387–95. doi:10.1161/CIRCULATIONAHA.109.928846.
44. Papaspyridonos M et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28:433–40. doi:10.1161/ATVBAHA.107.159160.
45. Sharma UC et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–8.
46. van Kimmenade RR et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217–24.
47. Felker GM et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012;5:72–8. doi:10.1161/CIRCHEARTFAILURE.111.963637.
48. Gullestad L et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33:2290–6. doi:10.1093/eurheartj/ehs077.
49. Anand IS et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15:511–8. doi:10.1093/eurjhf/hfs205.
50. Calvier L et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67–75. doi:10.1161/ATVBAHA.112.300569.
51. Fiuzat M et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 2014;20:38–44. doi:10.1016/j.cardfail.2013.11.011.
52. Gandhi PU et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015;169:404–411 e403. doi:10.1016/j.ahj.2014.12.012.
53. Ahmad T et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260–8. doi:10.1016/j.jchf.2013.12.004.
54. Yu L et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107–17. doi:10.1161/CIRCHEARTFAILURE.112.971168.
55. Stead Jr EA. Edema of heart failure. Bull N Y Acad Med. 1948;24:607–14.
56. Damman K, Tang WH, Testani JM, McMurray JJ. Terminology and definition of changes renal function in heart failure. Eur Heart J. 2014;35:3413–6. doi:10.1093/eurheartj/ehu320.
57. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36:1437–44. doi:10.1093/eurheartj/ehv010. This paper provides a comprehensive overview of the intricate relationship between the heart and kidney in heart failure.
58. Konstam MA. Renal function and heart failure treatment: when is a loss really a gain? Circ Heart Fail. 2011;4:677–9. doi:10.1161/CIRCHEARTFAILURE.111.964874.
59. Ahmad T, O'Connor CM. Therapeutic implications of biomarkers in chronic heart failure. Clin Pharmacol Ther. 2013;94:468–79. doi:10.1038/clpt.2013.139.
60. Brisco MA, Testani JM. Novel renal biomarkers to assess cardiorenal syndrome. Current Heart Fail Rep. 2014;11:485–99. doi:10.1007/s11897-014-0226-4.
61. 61 Damman, K., Voors, A. A., Navis, G., van Veldhuisen, D. J. & Hillege, H. L. Current and novel renal biomarkers in heart failure. Heart Fail Rev.
62. Troughton RW, Richards AM, Nicholls MG. Individualized treatment of heart failure. Intern Med J. 2001;31:138–41.
63. Troughton R, Michael Felker G, Januzzi Jr JL. Natriuretic peptide-guided heart failure management. Eur Heart J. 2014;35:16–24. doi:10.1093/eurheartj/eht463.
64. Felker GM et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail. 2014;2:457–65. doi:10.1016/j.jchf.2014.05.007.
65. Pitt B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92. doi:10.1056/NEJMoa1313731.
66. Allen LA. Use of multiple biomarkers in heart failure. Curr Cardiol Rep. 2010;12:230–6. doi:10.1007/s11886-010-0109-6.
67. Ky B et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183–90. doi:10.1161/CIRCHEARTFAILURE.111.965020.
68. Krumholz HM. Big data and new knowledge in medicine: the thinking, training, and tools needed for a learning health system. Health Aff. 2014;33:1163–70. doi:10.1377/hlthaff.2014.0053.
69. Januzzi Jr JL, Felker GM. Surfing the biomarker tsunami at JACC: heart failure. JACC Heart Fail. 2013;1:213–5. doi:10.1016/j.jchf.2013.03.007.